DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $12,716,000 | +1.7% | 49,231 | -0.2% | 1.22% | +8.7% |
| Q2 2022 | $12,501,000 | -14.9% | 49,309 | -1.4% | 1.12% | +0.4% |
| Q1 2022 | $14,682,000 | -8.5% | 50,032 | +2.6% | 1.12% | -4.0% |
| Q4 2021 | $16,045,000 | +7.2% | 48,767 | -0.8% | 1.16% | +0.8% |
| Q3 2021 | $14,974,000 | +12.2% | 49,172 | -1.1% | 1.16% | +13.5% |
| Q2 2021 | $13,350,000 | +22.7% | 49,726 | +2.8% | 1.02% | +10.4% |
| Q1 2021 | $10,882,000 | +4.2% | 48,349 | +2.9% | 0.92% | -0.5% |
| Q4 2020 | $10,439,000 | +0.2% | 46,993 | -2.9% | 0.93% | -6.8% |
| Q3 2020 | $10,418,000 | +20.5% | 48,380 | -1.1% | 1.00% | +10.2% |
| Q2 2020 | $8,647,000 | +26.6% | 48,900 | -0.9% | 0.90% | +4.8% |
| Q1 2020 | $6,832,000 | -11.7% | 49,358 | -2.0% | 0.86% | +13.3% |
| Q4 2019 | $7,734,000 | -3.4% | 50,391 | -9.1% | 0.76% | -4.6% |
| Q3 2019 | $8,003,000 | +0.8% | 55,413 | -0.3% | 0.80% | -2.8% |
| Q2 2019 | $7,943,000 | +10.0% | 55,576 | +1.6% | 0.82% | +6.1% |
| Q1 2019 | $7,218,000 | +28.5% | 54,675 | +0.4% | 0.77% | -15.5% |
| Q4 2018 | $5,616,000 | -6.5% | 54,457 | -1.5% | 0.92% | +53.2% |
| Q3 2018 | $6,006,000 | +14.6% | 55,275 | +4.1% | 0.60% | +7.7% |
| Q2 2018 | $5,242,000 | -0.6% | 53,121 | -1.4% | 0.56% | -5.6% |
| Q1 2018 | $5,274,000 | +2.5% | 53,868 | -2.8% | 0.59% | -2.5% |
| Q4 2017 | $5,146,000 | +8.2% | 55,438 | -0.0% | 0.60% | +1.5% |
| Q3 2017 | $4,756,000 | +1.8% | 55,440 | +0.1% | 0.59% | -2.0% |
| Q2 2017 | $4,674,000 | -1.2% | 55,388 | +0.2% | 0.61% | -6.3% |
| Q1 2017 | $4,730,000 | +7.8% | 55,304 | -1.8% | 0.65% | -2.4% |
| Q4 2016 | $4,386,000 | +2.0% | 56,345 | +2.8% | 0.66% | -2.5% |
| Q3 2016 | $4,298,000 | -22.8% | 54,830 | -0.6% | 0.68% | -25.6% |
| Q2 2016 | $5,570,000 | +1180.5% | 55,146 | +975.8% | 0.91% | +1187.3% |
| Q1 2016 | $435,000 | +16.0% | 5,126 | +26.8% | 0.07% | +14.5% |
| Q4 2015 | $375,000 | -8.8% | 4,043 | -15.8% | 0.06% | +5.1% |
| Q3 2015 | $411,000 | 0.0% | 4,801 | 0.0% | 0.06% | 0.0% |
| Q2 2015 | $411,000 | -5.5% | 4,801 | -6.3% | 0.06% | +293.3% |
| Q1 2015 | $435,000 | -0.9% | 5,126 | 0.0% | 0.02% | -28.6% |
| Q4 2014 | $439,000 | +12.9% | 5,126 | 0.0% | 0.02% | -16.0% |
| Q3 2014 | $389,000 | -3.7% | 5,126 | 0.0% | 0.02% | -13.8% |
| Q2 2014 | $404,000 | +1.0% | 5,126 | -4.0% | 0.03% | -12.1% |
| Q1 2014 | $400,000 | -1.2% | 5,338 | +1.7% | 0.03% | 0.0% |
| Q4 2013 | $405,000 | +11.3% | 5,248 | 0.0% | 0.03% | +3.1% |
| Q3 2013 | $364,000 | +9.6% | 5,248 | 0.0% | 0.03% | +3.2% |
| Q2 2013 | $332,000 | – | 5,248 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |